Eysins Switzerland 29 July 2024 AliveDx, a global in vitro diagnostics company that aims to transform patient care, today announced LumiQ™ – an innovative, automated immunofluorescence assay (IFA) solution. With this portfolio expansion, AliveDx can offer customers a differentiating, turnkey solution for autoimmune diagnostics with LumiQ IFA and groundbreaking MosaiQ® planar microarray technology.
“The addition of LumiQ is a logical and important step in our commitment to transform patient care through faster and more precise diagnosis,” stated Manuel O. Méndez, CEO of AliveDx. “Our customers are looking for partners to support them along the full autoimmune diagnostic pathway -with LumiQ’s IFA capabilities alongside MosaiQ we create value for customers by simplifying and accelerating their end-to-end autoimmune diagnostic workflows.”
The diagnostic workflow for various autoimmune diseases involves an antibody screening step, usually performed using IFA, and an identification step for confirmation. For example, the diagnosis of a CTD usually involves screening for ANA using IFA, as well performing a confirmatory test to identify known markers associated with these diseases. With AliveDx’s turnkey solution, customers will be able to use LumiQ and MosaiQ to perform screening and confirmatory tests, respectively. The intuitive workflow simplifies the complex diagnostic algorithms for autoimmune diseases. Both platforms offer high-throughput and true ‘sample to result’ automation to address the growing expectations for laboratory efficiency.
LUMIQ automates every step of the IFA workflow including slide preparation and image capture in an all-in-one solution that increases walkaway time. The solution provides recommendations for a positive and negative classification as well as pattern interpretation with an excellent level of confidence – aiding specialists in reading IFA results and contributing to improved consistency and reduced human error.
About AliveDx
At AliveDx, our mission is to empower diagnostic insights, transform patient care, and innovate for life. With over 30 years in in-vitro diagnostics, we aim to advance the future of diagnostics worldwide. We prioritize the health of patients and create innovative solutions that enable laboratories and clinicians to shorten the time to diagnosis. Our brands aim to create both economical and clinical value. We achieve this by simplifying laboratory workflows and delivering fast and accurate results that streamline clinical decision-making. At AliveDx, we innovate for life. We collaborate with laboratorians, clinicians, patient advocacy groups, academic institutions, and industry partners. When we feel ‘alive’, we do more than just live. Feeling alive is giving purpose, meaning and energy to our communities, our work and ourselves.
About the MosaiQ platform
MosaiQ® is a fully automated high-throughput platform that streamlines multiplex testing for Autoimmune, Allergy, and beyond. This intuitive platform delivers fast and accurate results using advanced microarray panels to rapidly detect and identify disease markers—maximizing workflow efficiencies, simplifying pathways, and helping shorten time to diagnosis.
For more information about AliveDx and its IVD solutions, please visit www.alivedx.com or connect with us on LinkedIn and X.
©AliveDx Suisse SA. 2024. The AliveDx logo, AliveDx, MosaiQ and LumiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. Subject to regulatory clearance.
